

**Cadila Healthcare Ltd. - Consolidated Gross Sales Break-up**

<b>Rs. Mio.</b>	<b>Q4 13-14</b>	<b>Q4 12-13</b>	<b>% Gr y-y</b>	<b>YTD 13-14</b>	<b>YTD 12-13</b>	<b>% Gr y-y</b>
<b>Domestic</b>	<b>8,136</b>	<b>7,411</b>	<b>9.8%</b>	<b>31880</b>	<b>29867</b>	<b>6.7%</b>
Formulations	6,247	5,708	9.4%	24,644	23,231	6.1%
API	209	138	51.3%	640	522	22.6%
Wellness	1,073	1,084	-1.0%	4,296	4,100	4.8%
Animal Health & Others	607	481	26.2%	2,300	2,014	14.2%
<b>Exports</b>	<b>10,273</b>	<b>7,429</b>	<b>38.3%</b>	<b>35,703</b>	<b>27,910</b>	<b>27.9%</b>
Formulations	<b>9,404</b>	<b>6,600</b>	<b>42.5%</b>	<b>32,281</b>	<b>24,885</b>	<b>29.7%</b>
US	6,783	3,882	74.7%	21,704	15,068	44.0%
Europe	845	961	-12.0%	3,902	3,697	5.5%
Japan	144	141	2.2%	541	603	-10.3%
Brazil	573	586	-2.3%	2,353	2,384	-1.3%
Mexico	24	0		109	0	
Emerging Mkts & Others	1,034	1,030	0.4%	3,673	3,134	17.2%
API	<b>731</b>	<b>721</b>	<b>1.3%</b>	<b>2,857</b>	<b>2,577</b>	<b>10.9%</b>
Animal Health & Others	<b>138</b>	<b>108</b>	<b>28.0%</b>	<b>565</b>	<b>448</b>	<b>26.1%</b>
<b>JVs &amp; Alliances</b>	<b>1,111</b>	<b>1,153</b>	<b>-3.6%</b>	<b>4,499</b>	<b>5,071</b>	<b>-11.3%</b>
<b>Total</b>	<b>19,520</b>	<b>15,993</b>	<b>22.1%</b>	<b>72,082</b>	<b>62,848</b>	<b>14.7%</b>

Cadila Healthcare Ltd.

Details of other incomes

Rs. Mio.	Q4 13-14	Q4 12-13	% Gr y-y	YTD 13-14	YTD 12-13	% Gr y-y
<b>Other Operating Income</b>	<b>522</b>	<b>459</b>	<b>13.5%</b>	<b>1,640</b>	<b>2,025</b>	<b>-19.0%</b>
Dossier Fees	8	0		8	2	300.0%
Royalty Income	75	304	-75.3%	301	600	-49.8%
Net Gain on foreign currency transactions and translation (Refer Note below)	-24	-92	74.0%	262	501	-47.7%
Others	462	247	87.2%	1,069	922	16.0%

Note : Apart from this loss, there was a net loss of Rs. 132 Mio. in Q4 13-14 on hedging and on translation of inventories held by foreign subsidiaries, which has been included in Cost of Goods. Thus, on aggregate level, there was a loss of Rs. 156 Mio. on operating transactions (above EBIDTA line) in Q4 13-14 vs loss of Rs. 189 Mio. in Q4 12-13. See details below for more clarity.

Rs. Mio.	Q4 13-14	Q4 12-13	% Gr y-y	YTD 13-14	YTD 12-13	% Gr y-y
<b>Other Income</b>	<b>131</b>	<b>87</b>	<b>50.3%</b>	<b>507</b>	<b>370</b>	<b>36.9%</b>
Interest & Dividend income	115	103	11.3%	388	321	20.7%
Profit on sale of investments	4	9	-52.1%	62	23	169.0%
Profit on sale of assets	0	0		0	0	
Others	12	-25	148.2%	57	26	119.7%

Details of Foreign Exchange Fluctuations

Rs. Mio. (+ = loss, - = gain)	Q4 13-14	Q4 12-13	% Gr y-y	YTD 13-14	YTD 12-13	% Gr y-y
<b>A. On operating transactions (above EBIDTA line)</b>	<b>156</b>	<b>189</b>	<b>-17.5%</b>	<b>359</b>	<b>174</b>	<b>106.3%</b>
a. Included in other income	24	93	-74.2%	-262	-500	47.6%
b. Included in sales				550		
c. Included in cost of goods	132	96	37.5%	71	674	-89.5%
<b>B. On Foreign Currency Borrowings (part of interest cost)</b>	<b>-31</b>	<b>-12</b>	<b>-162.7%</b>	<b>-278</b>	<b>425</b>	<b>-165.4%</b>
<b>Total Foreign Currency Fluctuations (+ = loss, - = gain)</b>	<b>125</b>	<b>177</b>	<b>-29.5%</b>	<b>81</b>	<b>599</b>	<b>-86.5%</b>

Details of R&D Expenses

Rs. Mio.	Q4 13-14	Q4 12-13	% Gr y-y	YTD 13-14	YTD 12-13	% Gr y-y
<b>Total R&amp;D Expenses</b>	<b>1,033</b>	<b>1,255</b>	<b>-17.7%</b>	<b>4,608</b>	<b>4,706</b>	<b>-2.1%</b>

Consolidated Capex for FY 2013-14

Rs. 4661  
Mio.

R&D capex included in above for FY 2013-14 :

Rs. 61  
Mio.